Thermal ablation of Barrett's esophagus: A heated debate

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A study reported in this issue of the American Journal of Gastroenterology has explored the efficacy of high-power argon plasma coagulation (APC) for the eradication of nonneoplastic Barrett's epithelium. Complete eradication was achieved in 77% of 48 patients, with a 10% rate of major complications including hemorrhage, esophageal stricture, and esophageal perforation. Although these observations indicate that high-power APC can eradicate Barrett's epithelium in some patients, it is not clear that this expensive and hazardous therapy conveys any clinical benefit. Even if one makes the substantial leap of faith that APC can decrease the risk of cancer in Barrett's esophagus, that risk is so small for patients without dysplasia that the number needed to treat is unacceptably large. Available data do not support the routine application of endoscopic ablative therapy for patients who have Barrett's esophagus without dysplasia.

Original languageEnglish (US)
Pages (from-to)1770-1772
Number of pages3
JournalAmerican Journal of Gastroenterology
Volume101
Issue number8
DOIs
StatePublished - Aug 2006

Fingerprint

Barrett Esophagus
Argon Plasma Coagulation
Hot Temperature
Esophageal Perforation
Esophageal Stenosis
Numbers Needed To Treat
Gastroenterology
Hemorrhage
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Thermal ablation of Barrett's esophagus : A heated debate. / Spechler, Stuart J.

In: American Journal of Gastroenterology, Vol. 101, No. 8, 08.2006, p. 1770-1772.

Research output: Contribution to journalArticle

@article{374b847f0a614c23a25b1d1412e74c6f,
title = "Thermal ablation of Barrett's esophagus: A heated debate",
abstract = "A study reported in this issue of the American Journal of Gastroenterology has explored the efficacy of high-power argon plasma coagulation (APC) for the eradication of nonneoplastic Barrett's epithelium. Complete eradication was achieved in 77{\%} of 48 patients, with a 10{\%} rate of major complications including hemorrhage, esophageal stricture, and esophageal perforation. Although these observations indicate that high-power APC can eradicate Barrett's epithelium in some patients, it is not clear that this expensive and hazardous therapy conveys any clinical benefit. Even if one makes the substantial leap of faith that APC can decrease the risk of cancer in Barrett's esophagus, that risk is so small for patients without dysplasia that the number needed to treat is unacceptably large. Available data do not support the routine application of endoscopic ablative therapy for patients who have Barrett's esophagus without dysplasia.",
author = "Spechler, {Stuart J.}",
year = "2006",
month = "8",
doi = "10.1111/j.1572-0241.2006.00706.x",
language = "English (US)",
volume = "101",
pages = "1770--1772",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Thermal ablation of Barrett's esophagus

T2 - A heated debate

AU - Spechler, Stuart J.

PY - 2006/8

Y1 - 2006/8

N2 - A study reported in this issue of the American Journal of Gastroenterology has explored the efficacy of high-power argon plasma coagulation (APC) for the eradication of nonneoplastic Barrett's epithelium. Complete eradication was achieved in 77% of 48 patients, with a 10% rate of major complications including hemorrhage, esophageal stricture, and esophageal perforation. Although these observations indicate that high-power APC can eradicate Barrett's epithelium in some patients, it is not clear that this expensive and hazardous therapy conveys any clinical benefit. Even if one makes the substantial leap of faith that APC can decrease the risk of cancer in Barrett's esophagus, that risk is so small for patients without dysplasia that the number needed to treat is unacceptably large. Available data do not support the routine application of endoscopic ablative therapy for patients who have Barrett's esophagus without dysplasia.

AB - A study reported in this issue of the American Journal of Gastroenterology has explored the efficacy of high-power argon plasma coagulation (APC) for the eradication of nonneoplastic Barrett's epithelium. Complete eradication was achieved in 77% of 48 patients, with a 10% rate of major complications including hemorrhage, esophageal stricture, and esophageal perforation. Although these observations indicate that high-power APC can eradicate Barrett's epithelium in some patients, it is not clear that this expensive and hazardous therapy conveys any clinical benefit. Even if one makes the substantial leap of faith that APC can decrease the risk of cancer in Barrett's esophagus, that risk is so small for patients without dysplasia that the number needed to treat is unacceptably large. Available data do not support the routine application of endoscopic ablative therapy for patients who have Barrett's esophagus without dysplasia.

UR - http://www.scopus.com/inward/record.url?scp=33746708126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746708126&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2006.00706.x

DO - 10.1111/j.1572-0241.2006.00706.x

M3 - Article

C2 - 16928252

AN - SCOPUS:33746708126

VL - 101

SP - 1770

EP - 1772

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 8

ER -